MediciNova, Inc.

MediciNova is a clinical-stage biopharmaceutical company whose drug development pipeline necessitates animal testing as a core component of its preclinical research. The company’s public filings, including its annual reports on Form 10-K, explicitly cite the “completion of nonclinical laboratory, animal studies, and formulation studies” as a routine part of its development process. This places MediciNova within the category of pharmaceutical firms that rely on animal models for regulatory compliance and safety assessment of its investigational compounds. The company’s research areas, which have included investigating treatments for drug addiction and withdrawal, typically involve animal studies in early-stage development to assess efficacy and toxicity. While some industry efforts aim to reduce animal testing through advanced models, MediciNova’s disclosed development activities confirm its ongoing use of animals in research.